Related Experiment Video
Updated: Dec 3, 2025
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
EPIGENETIC CHANGES IN MALIGNANT UVEAL MELANOMA AND POSSIBILITIES OF THEIR THERAPEUTIC TARGETING
Abstract:
Uveal melanoma (UM) is a deadly cancer that leads to metastatic disease in more than 50 % of the patients. Despite the improvement in the treatment of primary disease, there is still no effective therapy to prevent the development of metastases. Therefore, the disease requires intensive research to identify new treatment strategies. In preclinical UM models, epigenetic drugs have been shown to increase the sensitivity of resistant tumour cells to treatment. The successful use of histone deacetylase inhibitors, which induced cell cycle arrest, reprogramming consistent with melanocyte differentiation and inhibition of tumour growth in preclinical models, demonstrates the role of epigenetic regulation in UM metastasis. Identification of epigenetic changes associated with UM development an progression could contribute to the discovery of more effective drugs that, in combination with traditional approaches, may yield better therapeutic results for high-risk patients.
Insights
Uveal melanoma (UM) is a deadly cancer. Epigenetic drugs show promise in preclinical models by increasing sensitivity to treatment and inhibiting tumor growth, offering new therapeutic strategies.
Area of Science:
- Oncology
- Cancer Research
- Epigenetics
Background:
- Uveal melanoma (UM) is an aggressive eye cancer with a high rate of metastasis.
- Current treatments for primary UM lack efficacy in preventing metastatic disease.
- There is a critical need for novel therapeutic strategies to combat UM metastasis.
Purpose of the Study:
- To explore the role of epigenetic regulation in uveal melanoma metastasis.
- To investigate the potential of epigenetic drugs in overcoming treatment resistance in UM.
- To identify epigenetic changes associated with UM development and progression for targeted therapy.
Main Methods:
- Utilized preclinical UM models to assess the effects of epigenetic drugs.
- Examined the impact of histone deacetylase inhibitors on tumor cell behavior.
- Analyzed epigenetic modifications linked to UM progression.
Main Results:
- Epigenetic drugs enhanced the sensitivity of resistant UM cells to treatment in preclinical settings.
- Histone deacetylase inhibitors induced cell cycle arrest and promoted differentiation.
- Epigenetic drug administration inhibited tumor growth in preclinical UM models.
Conclusions:
- Epigenetic regulation plays a significant role in UM metastasis.
- Epigenetic drugs represent a promising avenue for novel UM treatment strategies.
- Targeting epigenetic changes could lead to more effective combination therapies for high-risk UM patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle